• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
COVID-19 and Women’s Health

More Evidence That Vaccination Against COVID During Pregnancy Isn’t Linked to Adverse Outcomes

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Magnus et al. (JAMA, 2022) examined the risk of adverse pregnancy outcomes after vaccination against SARS-CoV-2 during pregnancy

METHODS:

  • Registry-based retrospective cohort study
    • Norway and Sweden
    • January 2021 through January 2022
  • Population
    • Singleton pregnancies
    • Delivery after ≥22 weeks
  • Exposures
    • Vaccination: Pfizer | Moderna | AstraZeneca
  • Study design
    • Risk of primary outcomes were evaluated using Cox regression models
    • Vaccination served as a time-dependent exposure variable
    • Risk of secondary outcomes were evaluated using logistic regression
    • Random-effects meta-analysis was used to combine results between countries
  • Primary outcomes
    • Preterm birth and stillbirth
  • Secondary outcomes
    • Small for gestational age
    • Low Apgar score
    • Neonatal care admission

RESULTS:

  • 157,521 pregnancies
    • Mean maternal age at delivery: 31 years
    • Vaccinated against COVID-19 while pregnant: 18%
      • Pfizer: 12.9%
      • Moderna: 4.8%
      • AstraZeneca: 0.3%
    • Vaccinated during
      • First trimester: 0.7%
      • Second trimester: 8.3%
      • Third trimester: 9.1%
  • Vaccination against SARS-CoV-2 was not significantly associated with increased risk of
    • Preterm birth
      • Vaccinated: 6.2 per 10,000 pregnancy days
      • Non-vaccinated: 4.9
      • Adjusted hazard ratio (aHR) 0.98 (95% CI, 0.91 to 1.05)
    • Stillbirth
      • Vaccinated: 2.1 per 10,000 pregnancy days
      • Non-vaccinated: 2.4
      • aHR 0.86 (95% CI, 0.63 to 1.17)
    • Small for gestational age
      • Vaccinated: 7.8%
      • Non-vaccinated: 8.5%
      • Difference –0.6% (95% CI, –1.3 to 0.2)
      • Adjusted OR (aOR) 0.97 (95% CI, 0.90 to 1.04)
    • Low Apgar score
      • Vaccinated: 1.5%
      • Non-vaccinated: 1.6%
      • Difference –0.05% (95% CI, –0.3 to 0.1)
      • AOR 0.97 (95% CI, 0.87 to 1.08)
    • Neonatal care admission
      • Vaccinated: 8.5%
      • Non-vaccinated: 8.5%
      • Difference 0.003% (95% CI, –0.9 to 0.9)
      • AOR 0.97 (95% CI, 0.86 to 1.10)

CONCLUSION:

  • COVID-19 vaccination during pregnancy was not associated with an increased risk of adverse pregnancy outcomes
  • Most of the vaccinations in this population occurred during the second and third trimester
  • The authors state

COVID-19 in pregnancy is also associated with adverse pregnancy outcomes affecting the child, and vaccination reduces the risk of COVID-19 during pregnancy

An added benefit of vaccination of individuals against SARS-CoV-2 during pregnancy is that antibodies are transferred to the fetus, which offers infants protection against the virus during the first months of life

This is particularly beneficial because none of the existing vaccines are currently approved for use in children younger than 2 years

Learn More – Primary Sources:

Association of SARS-CoV-2 Vaccination During Pregnancy With Pregnancy Outcomes

Get Mobile-Friendly COVID-19 Research Summaries with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All COVID-19 and Women’s Health Posts
Next >

Related ObG Topics:

Does Maternal COVID-19 Vaccination Protect Against Infant Hospitalization Due to COVID?
COVID-19 Vaccination Does Not Increase Risk of Preterm Birth or SGA
COVID-19 Vaccination and Miscarriage: Another Study Finds No Link
Prospective Data: COVID-19 Vaccinations Rates and Associated Pregnancy Outcomes
Is There Any Evidence of a Link Between COVID-19 Vaccines and Spontaneous Abortion?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site